Pulmokine Overview
- Founded
- 2007
- Status
- Private
- Latest Deal Type
- 2ndary - Private
- Investors
- 3
Pulmokine General Information
Description
Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology treats crucial lung conditions, enabling patients suffering from lung diseases to access pulmonary drugs.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
- 7 University Place
- Room B127
- Rensselaer, NY 12144
- United States
+1 (518) 000-0000
Pulmokine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 000 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2017 | 00000 | 000 | Completed | Generating Revenue | |
| 4. Grant | 01-Jan-2016 | 00.000 | 000 | Completed | Generating Revenue | |
| 3. Seed Round | 04-Mar-2015 | 000 | 000 | Completed | Generating Revenue | |
| 2. Debt - General | 01-Oct-2014 | Completed | Generating Revenue | |||
| 1. Grant | 27-Mar-2014 | $1.5M | Completed | Generating Revenue |
Pulmokine Executive Team (5)
Pulmokine Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Shreefal Mehta Ph.D | Self | Board Director | 000 0000 |